Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report?

Exelixis (EXEL) shares have declined 7.2% since its last earnings report, underperforming the S&P 500, despite upward revisions in consensus estimates which have shifted 15.91%. The stock holds a Zacks Rank #2 (Buy), suggesting an expected above-average return in the coming months, and boasts a strong VGM Score of A. Meanwhile, Puma Biotech (PBYI), a peer in the same industry, has gained 22.1% over the past month, reporting revenues of $46 million (+5% year-over-year) and EPS of $0.10, with expectations of $0.11 EPS for the current quarter (+320% from the year-ago quarter).

Analysis

Exelixis (EXEL) has experienced a notable divergence between its recent stock performance and its underlying analytical metrics. Shares have declined 7.2% since its last earnings report, underperforming the S&P 500. However, during this same period, consensus estimates for Exelixis have trended upward significantly, with a 15.91% positive shift. The company maintains strong fundamental indicators, including a Growth Score of A, a Momentum Score of A, and a Value Score of B, culminating in an aggregate VGM Score of A. Furthermore, Exelixis holds a Zacks Rank #2 (Buy), indicating an expectation of above-average returns in the near term. In contrast, Puma Biotech (PBYI), an industry peer within the Zacks Medical - Biomedical and Genetics sector, has seen its stock gain 22.1% over the past month. Puma Biotech reported a 5% year-over-year revenue increase to $46 million in its last quarter and an EPS of $0.10, a significant improvement from -$0.05 a year ago. For the current quarter, Puma Biotech is projected to achieve an EPS of $0.11, representing a 320% year-over-year increase, and also holds a Zacks Rank #2 (Buy) with a VGM Score of A. This juxtaposition highlights that while Exelixis shares have lagged, its revised estimates and fundamental scores suggest potential for a positive trajectory.

Key Decisions for Investors

• Investors might consider the recent 7.2% pullback in Exelixis shares as a potential opportunity, given the concurrent 15.91% upward revision in consensus estimates and its strong VGM Score of A.
• The Zacks Rank #2 (Buy) for Exelixis suggests an expectation of above-average returns, which contrasts with its recent share price underperformance and warrants further investigation into the disconnect.
• Monitor Exelixis for signs of a breakout, as its positive estimate revisions and fundamental strength may not yet be fully reflected in its stock price, especially when compared to the strong performance of similarly-rated peers like Puma Biotech.